Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

Abstract

Treatment with canakinumab in patients with COVID-19-related pneumonia rapidly restored normal oxygen status, decreased the need for invasive mechanical ventilation, and was associated with earlier hospital discharge and favourable prognosis versus standard of care.